HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute
Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute image
HealthTree Podcast for Multiple Myeloma
event May 16, 2014 / 11:00AM - 12:00PM MDT

Event Description

Learn about all myeloma happenings on the new Myeloma Crowd site: the first comprehensive site for myeloma patients and caregivers. Dr. Paul Richardson, MD Jerome Lipper Center for Multiple Myeloma Dana-Farber Cancer Institute Interview Date: May 16, 2014

 Dr. Paul Richardson, a key leader of significant national and international myeloma clinical trials, shares three platforms for today's therapies: targeting the tumor environment, leveraging the immune system, and targeting how and when myeloma mutates. The latest in immunotherapies includes fast-tracking new monoclonal antibodies like elotuzumab (targeting protien CS1/SLAMF7) and daratumumab and SAR (targeting protein CD38), re-activating normal T cell functions by affecting the PD-1 pathway, and using vaccines to impact the immune system. He describes a new clinical trial that is studying multiple questions at the same time: the DETERMINATION study (see link) will have 1300 patients (700 in France and over 600 in the US) to determine when transplant is best used in newly diagnosed myeloma patients now that newer therapies are available. The study will also look at how the Revlimid/Velcade/Dex combo works as initial treatment and how lenalidomide affects progression as maintenance therapy. He gives a preview of his upcoming discussion at ASCO on panobinostat; that its use with dex and bortezomib is better than dex and bortezomib alone. He describes a mind-body peace study at Dana-Farber that shows how stress activates cell signaling pathways and the proof that using relaxation techniques can make a difference in myeloma growth because of the NF-kappaB pathway. He recommends that patients should consider continuous maintenance therapy until progression and cites studies showing the importance. He also suggests that any time patients have a bone marrow biopsy, they should request cytogenetics and FISH tests at the same time to keep an overarching picture of their personal disease biology in place. The live mPatient Myeloma Radio podcast with Dr. Paul Richardson

Schedule & Agenda

Dr. Paul Richardson & Jennifer Ahlstrom

Speakers & Moderators

The panelist Paul Richardson, MD
Paul Richardson, MD

Paul Richardson, MD, is the RJ Corman Professor of Medicine at the Harvard Medical School, Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, of the Dana-Farber Cancer Institute (DFCI) in Boston. Dr. Richardson received his medical degree from the Medical College of St. Bartholomew’s Hospital in London, UK. His postdoctoral training included internship in the Departments of Medicine & Surgery at St. Bartholomew’s Hospital; residency in the Department of Medicine at Newcastle University School of Medicine; appointment as Chief Resident in Medical Oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston, USA. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute before coming on staff at DFCI in 1994. Dr. Richardson currently holds leadership positions in several professional bodies and serves on the Editorial Board of the Journal of Clinical Oncology, the Journal of Oncology, The Oncologist, Clinical Cancer Research, and the British Journal of Hematology. He is the prior Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core, a position he held for 5 years as a founding member and as part of a rotating tenure, and for which he continues to serve on the Steering Committee and Project Review Committee. He now chairs the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). His honors include several Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Partners in Excellence Awards; The Brigham and Women’s Hospital Teaching Scholars Award; The Tisch Outstanding Achievement Award for Clinical Research; and the Dana-Farber Cancer Institute’s George Canellos Award for Excellence in Clinical Research and Patient Care. For his contributions in hematology and oncology, and in particular myeloma, he was awarded an honorary Fellowship of the Royal College of Physicians (FRCP) in 2009, and he was also more recently a co-recipient of the prestigious Warren Alpert Prize in 2012, the Ernest Beutler Prize at ASH 2015, and the Robert A Kyle Lifetime Achievement Award in 2017.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube